NICE greenlights Consilient Health’s Elmiron for bladder pain syndrome

pharmafile | November 14, 2019 | News story | Sales and Marketing NICE, consilient health, elmiron, pharma 

NICE has chosen to recommend Consilient Health’s Elmiron (pentosan polysulfate sodium) for the treatment of bladder pain syndrome (BPS), it has emerged, for patients whose condition has not responded to oral treatments and are not offered the drug in combination with bladder instillations.

The decision was reached as the two parties agreed to a patient access scheme to make the drug available to NHS patients.

In regards to the decision, BPS is defined as chronic pain, discomfort or pressure in the pelvic region combined with at least one other urinary symptom.

“This is a condition with a significant unmet clinical need and the company is delighted that Elmiron has been recommended for the treatment of IC/BPS,” commented Amanda Paxon, Country Manager, Pharmaceuticals at Consilient Health UK.

Advertisement

Susannah Fraser, Communication and Media Manager at Bladder Health UK, also remarked on the news: “BPS is a debilitating condition and has a considerable detrimental impact on the individual’s lifestyle, ability to work, emotional health and relationships. Their quality of life is hugely compromised. For individuals to be able to access Elmiron on the NHS is really good news.”

Matt Fellows

Related Content

Combination treatments: Takeda’s Implementation Framework and the broader landscape

Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS

Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …

The Gateway to Local Adoption Series

Latest content